Malignant pleural effusion is a build-up of fluid in the chest that can develop in some patients with mesothelioma or other cancers in the chest. In this study, researchers are determining the highest dose of an investigational drug called GL-ONC1 that can be given safely in patients with malignant pleural effusion due to pleural mesothelioma, primary lung cancer, or lung metastases.
GL-ONC1 is a modified, weakened strain of a virus called vaccinia. It is designed to locate, enter, and destroy cancer cells without harming healthy tissues. Laboratory studies showed that GL-ONC1 targeted and killed cancer cells.